HRTX

Heron Therapeutics, Inc.

$0.83 -4.93%

Recent alerts on HRTX

All signals →

News Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner

News FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma

News AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer

News FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder

News OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies

News Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why

News FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D

News Avidity (RNA) Up 33% on Rare Muscle Disease Study Results

News Eli Lilly (LLY) Veteran Anat Ashkenazi to Join Alphabet as CFO

News Amgen's (AMGN) Uplizna Meets Study Goal for Rare Disease

News Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study

News Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody

News Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data

News Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty

News Merck (MRK) to Buy Private Ophthalmology Company EyeBio

News J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms

News Iovance (IOVA) Up 5% on Updated Data From Melanoma Study

News Is CareCloud (CCLD) Outperforming Other Medical Stocks This Year?

News Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data

News Moderna (MRNA) Stock Outperformed Industry YTD: Here's Why

News Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027

News What Makes Heron Therapeutics (HRTX) a Strong Momentum Stock: Buy Now?

News Heron outlines $173M-$183M 2026 net product sales outlook as it targets return to positive adjusted EBITDA

News Heron Therapeutics misses top-line and bottom-line estimates; reaffirms FY26 outlook

SEC filing HRTX Reports $34.7M Q1 Revenue, +32% Acute Care Growth, Reaffirms $173-183M FY Guidance

Get push alerts for HRTX

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS